Pediatric Diabetes Therapeutic Market to Reach US$ 2612.4 Million By 2034 Amid Growing Emphasis on Healthcare Innovations Worldwide 

Pediatric Diabetes Therapeutic Market

According to Future Market Insights (FMI), the worldwide Pediatric Diabetes Therapeutic Market is estimated to reach US$ 1633.8 million in 2024 and US$ 2612.4 million by 2034. The market is projected to rise at a CAGR of 4.8% from 2024 to 2034.

Growing awareness among parents concerning the rising prevalence of diabetes among the pediatric population plays an important role in the diagnosis of the disease. Rising diabetes incidence and sedentary lifestyle changes are the key factors fueling growth. Technological development in diabetes drug systems is further propelling demand for pediatric diabetes therapeutics.

Key manufacturers and companies are prioritizing pediatric safety and tolerability studies for approval of their existing drugs, thereby boosting growth. The surge is further bolstered by the continuous efforts of healthcare authorities to enhance and escalate their regional healthcare facilities and services.

Increasing research and development efforts in pediatrics for new drugs for managing stage 3 diabetes are projected to create ample opportunities for manufacturers. Pharmaceutical manufacturers are set to enhance their global market presence by partnering with non-profit organizations and children’s hospitals to launch awareness programs.

Request The Sample Copy of This Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-19589

Key Takeaways from the Pediatric Diabetes Therapeutic Market Study

• By diabetes, the type 1 diabetes segment is set to surge at a CAGR of 2 by 2034.
• By route of administration, the parenteral administration segment accounted for a leading share of 4%in the market.
• By distribution channels, the institutional sales segment is projected to lead the market at a CAGR of 4.2%by 2034.
• The United States is set to rise at 4%CAGR by 2034.
• By country, China is projected to surge at 3%CAGR during the forecast period.

“Growing popularity of e-tail and e-commerce has led to the potential of online pharmacies as a promising segment for developing the pediatric diabetes therapeutic market. Governments and healthcare organizations worldwide are exploring biosimilars to improve affordability and patient accessibility,” says a lead analyst at Future Market Insights (FMI).

Pediatric Diabetes Therapeutic Market Competitive Landscape

Leading manufacturers are focusing on research and development of novel therapeutic options to broaden their product portfolio and reach a wide audience. Key companies are directed towards partnerships, collaborations, and alliances to enhance their research, development, and commercialization expertise.

For instance,

• In March 2023, Sanofi, headquartered in France, acquired Provention Bio, a United States-based Biopharmaceutical Company.
• In 2023, AstraZeneca, headquartered in the United Kingdom, received marketing authorization for Bydureon BCise in Europe.

Leading Pediatric Diabetes Therapeutic Brands

• Boehringer Ingelheim International GmbH
• Eli Lilly and Company
• Sanofi
• Vertex Pharmaceuticals Incorporated
• Novo Nordisk A/S
• AstraZeneca
• MannKind Corporation
• Xeris Pharmaceuticals
• Amphastar Pharmaceuticals, Inc.

Purchase The Full Report Now!
https://www.futuremarketinsights.com/checkout/19589

Key Segments of Pediatric Diabetes Therapeutic Market Report

By Diabetes:

In terms of diabetes, the category is divided into type 1 and type 2.

By Therapy:

The industry is segregated into drug therapy and insulin therapy. Drug therapy is further divided into biguanide and sodium-glucose co-transporter 2 (SGLT2) inhibitors. Insulin therapy is sub-segmented into rapid-acting insulin, short-acting insulin, intermediate-acting insulin, and long-acting insulin.

By Route of Administration:

The industry is segregated into oral administration, nasal administration, and parenteral administration. The parental administration segment is further trifurcated into subcutaneous, intramuscular, and intravenous.

By Distribution Channel:

A few of the important distribution channels include institutional sales, retail sales, and online pharmacy. Further, the institutional sales segment is branched into hospitals, specialty clinics, and others. Along with that, the retail sales segment is divided into retail pharmacies and drug stores.

By Region:

Key countries of North America, Latin America, East Asia, South Asia and Pacific, Western Europe, Eastern Europe, and the Middle East and Africa are covered.

Want More Insights?

Future Market Insights (FMI) brings a comprehensive research report on predicted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2019 to 2034. The global pediatric diabetes therapeutic market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights into the pediatric diabetes therapeutic market segment based on diabetes (type 1 and type 2) therapy (drug therapy [biguanide and sodium-glucose co-transporter 2 (SGLT2) inhibitors], and insulin therapy [rapid acting insulin, short-acting insulin, intermediate-acting insulin, and long-acting insulin]), route of administration (oral administration, nasal administration, and parenteral administration [subcutaneous, intramuscular and intravenous]), distribution channel (institutional sales [hospitals, specialty clinics, and others], retail sales [retail pharmacies, and drug stores] and online pharmacy) across regions.

About Healthcare Division at Future Market Insights

Future Market Insights (FMI) facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you to devise innovation-driven trajectories for your business.

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges clients face and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube